Navigation Links
For Patients Who Fail on Viagra, Levitra or Cialis
Date:10/29/2008

TriMix Laboratories Announces Major Product Enhancement

CHERRY HILL, N.J., Oct. 29 /PRNewswire/ -- TriMix Laboratories LLC today announced a major enhancement to their flagship product TriMix-gel(TM). TriMix-gel(TM) uses the ED gel(TM) (pat. pend.) applicator system. The applicator has been fitted with an adapter to make the use of TriMix-gel(TM) even easier for the patient. The adapter will be included for shipment to patients immediately.

The new adapter is featured on the website http://www.trimixgel.com. A video there includes a demonstration of an actual patient applying the medicine. TriMix Laboratories President T.J. Harkins says, "The innovative nature of the TriMix-gel(TM) applicator makes it hard to describe in a small sound bite. This video is an important tool in helping ED patients understand how valuable TriMix-gel(TM) can be for them."

TriMix-gel(TM) has been used by doctors as an alternative erectile dysfunction (ED) treatment. Doctors prescribe TriMix-gel(TM) for patients who have failed on Viagra, Levitra or Cialis type tablets or who cannot tolerate their side effects. Trimix ingredients have been tested and widely prescribed for many years for improvement of sexual health.

TriMix-gel(TM) contains active ingredients which are classified as medicine and are listed in the US Pharmacopoeia. Therefore, a patient would need a prescription from his physician to obtain TriMix-gel(TM). For an order form, visit http://www.trimixgel.com and click the prescription form. The patient gives the form to the doctor. The doctor faxes the prescription to the pharmacy at 877-387-4649 and the pharmacy ships the medicine directly to the patient.

Typically, the trimix liquid for injection version of the compound would have to be refrigerated and then self injected with a needle at time of use. But the compound in gel form, called TriMix-gel(TM), allows the patient to carry the medicine at room temperature. More importantly, an ED patient will not have to use a needle to self inject before sexual intercourse.

Recently, clinical trials were performed on TriMix-gel(TM). All the test patients were men who failed on Viagra, Levitra or Cialis tablets. These patients were given TriMix-gel(TM). All the test patients received some degree of positive effect from TriMix-gel(TM) in the form of tumescence (enlargement). It was determined that 40% of the test patients achieved a result sufficient for sexual intercourse over Viagra, Levitra or Cialis tablets.

The trial results were published in the Journal of Urology Supplement, J. Urol. 179 (4): 431, 2008. For more information, visit http://www.trimixgel.com and click "Drug Studies."

TriMix Laboratories President T.J. Harkins said, "Our test patients were very impressed with the 'ease of use.' We are happy our new adapter is so well received."

TriMix Laboratories LLC is a medical research and marketing firm specializing in the urological subspecialty of erectile dysfunction. The information contained herein is general in nature and is intended for use only as an informational aid. It does not cover all possible uses, actions, precautions, side effects, or interactions of the products shown, nor is the information intended as medical advice or diagnosis for individual health problems. TriMix-gel(TM) has not been evaluated by the Food and Drug Administration ("FDA"). TriMix-gel(TM) is not made under GMP requirements. It is compounded in a licensed compounding pharmacy for the use of an individual patient who has been prescribed TriMix-gel(TM) by a licensed physician. It is not intended for making an evaluation as to the risks and benefits. Before taking any action, consult your Doctor.

Contact: T.J. Harkins

TriMix Laboratories

Cherry Hill, NJ

856-428-7008


'/>"/>
SOURCE TriMix Laboratories LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Fluctuating eye pressure associated with visual field deterioration in glaucoma patients
2. Comparison of obstetric outcomes between on-call and patients own obstetricians
3. Vision restoration therapy shown to improve brain activity in brain injured patients
4. Diabetes appears to increase risk of death for patients with acute coronary syndromes
5. Ambulatory oxygen rarely a benefit in COPD patients without resting hypoxemia
6. Restricting Blood Flow May Help Heart Bypass Patients
7. Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer
8. Study provides hope that some transplant patients could live free of antirejection drugs
9. Study provides hope that some transplant patients could live free of anti-rejection drugs
10. Longer ambulance journeys boost death risk for seriously ill patients
11. Expenses Overshadow Optimism for Kidney Failure Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 24, 2017 , ... ... to Thrive , Well-meaning studies such as the Fordham Institute’s High Stakes ... serve top students, such as including gifted or high-achieving students as a subgroup ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... Pollack, Ph.D., http://www.faculty.washington.edu/ghp , Sharon Kleyne, the nation’s foremost water advocate ... Global Climate Change and Your Health on Voice America, once again welcomed one ...
(Date:1/24/2017)... ... ... A yellow fever outbreak in Brazil has infected over 100 people and claimed ... contact with infected mosquitos. The outbreak has sparked increased concern about the virus and ... multiple health organizations, the best way to prevent yellow fever is through vaccination. For ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... topics like finances, friendship, marriage, leadership, gossip, prostitution, adultery, anger, and common sense. ... authors, Dr. Judith Coats and Dr. David Coats. In September of 1983, they ...
(Date:1/24/2017)... ... , ... “Mysteries Revealed On Speaking In Tongues”: an engaging and dynamic ... Christians. “Mysteries Revealed On Speaking In Tongues” is the creation of published author, Tina ... located in Michigan. , “We need to partner with Jesus and be the ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... India , Jan. 24, 2017 Market Research Future has ... Market for Wound Closure Device is growing rapidly and expected to continue ... ... at a CAGR of 5% from 2013 to 2019 and reaching a ... of the forecasted period, 2016-2022 Global Wound Closure Device Market ...
(Date:1/24/2017)... Nev. , Jan. 24, 2017  The ... that specializes in high-value orthopaedic implants, announced the ... today. The OIC Tibial Nail ... tibia. Strategically placed proximal and distal screw holes ... hole that allows dynamization.  The nail is available ...
(Date:1/24/2017)... 2017 Trifecta Clinical , a leading ... Rick Ward to Vice President of Commercial ... also announcing the promotion of Ericka Atkinson ... Rick joins Trifecta from Greenphire where he was ... business development positions within the healthcare industry throughout his ...
Breaking Medicine Technology: